Heart failure guidelines recommend four HFrEF medications, but most patients aren’t on the right drugs and doses. See the benefits and how we connect patients with life-improving care.
ALS, or Lou Gehrig's disease, slowly robbed Rupesh Kotiya of his ability to speak, move, and breathe on his own. But the neurodegenerative disease could not take away his chance to help others. He made the ultimate sacrifice and set a lasting example for his two young sons.
Cardiac amyloidosis was once considered untreatable. Now, we have effective treatments, less invasive diagnostic tests, and a growing body of research in this complex disease.
New AHA guidelines highlight the benefits of SGLT2i medications for patients with heart failure and advances in diagnosing and treating ATTR amyloidosis.
A surprise finding in SGLT2 inhibitor drug research has revealed a potentially groundbreaking heart failure treatment. Learn more from UT Southwestern.
The concept of regenerating or growing heart tissue is not far-fetched. Ongoing research by UT Southwestern may potentially change the future of care for patients with mild to moderate heart disease.
Before her 50th birthday, heart transplant recipient Susan Liang has survived more than her fair share of challenges. Read her remarkable story of how UT Southwestern gave her a "fourth chance at life."
Video visits are an effective, high-quality alternative to in-clinic visits for patients with advanced heart failure. Find out what to expect and how remote care can benefit patients.
A diagnosis of advanced heart failure sounds ominous, but the key to managing the condition is detecting it early. UT Southwestern shares six simple clues that can help patients recognize advanced heart failure so they get the specialized treatment they need.
After years of steady decline, heart disease death rates have increased 1.5% among the 45-60 age group – right in the prime of their personal and professional lives. In this MedBlog, UT Southwestern discusses the major causes and how preventive cardiology can help reverse this alarming trend.
Left ventricular assist devices (LVAD) can help patients with advanced heart failure live longer and give them a better quality of life. UT Southwestern answers four common questions he gets from patients about LVADs.
Newly published comparative data on survival outcomes among the three heart transplant programs in Dallas give UT Southwestern cause to be proud. Learn more.
Nearly 4,000 people across the U.S. are waiting for a heart transplant, and there aren’t enough donor hearts to go around. Discover what the future of heart transplantation might hold and how Texans can help narrow the gap today.
